Investors soured on the sector when Elevance, an insurer, handed in disappointing results and shared a downbeat outlook.

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Over the last 7 days, the United States market has remained flat, yet it has experienced a notable 12% rise over the past year with earnings forecasted to grow by 15% annually. In such an environment, ...

J&J (NYSE:JNJ) stock surges rallying peers despite Trump's latest tariff threats on pharma as the company posts a quarterly ...

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's ...

If you have $1,000 to invest right now, you may be wondering where to get started. You could buy stocks that are flying high ...

This week, Phil Oakley has analysed two shares, DexCom (US:DXCM) and Auto Trader (AUTO), which have decent earnings growth forecasts but rich valuations. It looks like both companies will need ...

Pfizer has caught investors’ eyes recently, outperforming its peers slightly but facing modest growth prospects ahead.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.